全文获取类型
收费全文 | 1687882篇 |
免费 | 126673篇 |
国内免费 | 3789篇 |
专业分类
耳鼻咽喉 | 21761篇 |
儿科学 | 55557篇 |
妇产科学 | 46206篇 |
基础医学 | 240176篇 |
口腔科学 | 48907篇 |
临床医学 | 150514篇 |
内科学 | 332134篇 |
皮肤病学 | 38679篇 |
神经病学 | 130572篇 |
特种医学 | 63875篇 |
外国民族医学 | 242篇 |
外科学 | 257435篇 |
综合类 | 38848篇 |
现状与发展 | 4篇 |
一般理论 | 531篇 |
预防医学 | 123466篇 |
眼科学 | 40098篇 |
药学 | 123755篇 |
7篇 | |
中国医学 | 4365篇 |
肿瘤学 | 101212篇 |
出版年
2019年 | 13601篇 |
2018年 | 20054篇 |
2017年 | 15293篇 |
2016年 | 16699篇 |
2015年 | 19036篇 |
2014年 | 26325篇 |
2013年 | 38089篇 |
2012年 | 52985篇 |
2011年 | 55655篇 |
2010年 | 32904篇 |
2009年 | 30805篇 |
2008年 | 51730篇 |
2007年 | 55072篇 |
2006年 | 55500篇 |
2005年 | 52804篇 |
2004年 | 50958篇 |
2003年 | 48256篇 |
2002年 | 46496篇 |
2001年 | 91824篇 |
2000年 | 93585篇 |
1999年 | 76738篇 |
1998年 | 18823篇 |
1997年 | 16320篇 |
1996年 | 16460篇 |
1995年 | 16701篇 |
1994年 | 15262篇 |
1993年 | 14042篇 |
1992年 | 57423篇 |
1991年 | 55363篇 |
1990年 | 53038篇 |
1989年 | 50827篇 |
1988年 | 46203篇 |
1987年 | 45008篇 |
1986年 | 42273篇 |
1985年 | 40063篇 |
1984年 | 29375篇 |
1983年 | 24897篇 |
1982年 | 13870篇 |
1981年 | 12355篇 |
1979年 | 25523篇 |
1978年 | 17574篇 |
1977年 | 14890篇 |
1976年 | 13868篇 |
1975年 | 14536篇 |
1974年 | 17637篇 |
1973年 | 16934篇 |
1972年 | 15702篇 |
1971年 | 14459篇 |
1970年 | 13449篇 |
1969年 | 12544篇 |
排序方式: 共有10000条查询结果,搜索用时 171 毫秒
41.
Laurien J. Zeverijn Eleonora J. Looze Subotheni Thavaneswaran J. Maxime van Berge Henegouwen Robert J. Simes Louisa R. Hoes Katrin M. Sjoquist Hanneke van der Wijngaart Lucille Sebastian Birgit S. Geurts Chee K. Lee Gijsbrecht F. de Wit David Espinoza Paul Roepman Frank P. Lin Anne M. L. Jansen Wendy W. J. de Leng Vincent van der Noort Lindsay V. M. Leek Filip Y. F. L. de Vos Carla M. L. van Herpen Hans Gelderblom Henk M. W. Verheul David M. Thomas Emile E. Voest 《International journal of cancer. Journal international du cancer》2023,153(7):1413-1422
The Dutch Drug Rediscovery Protocol (DRUP) and the Australian Cancer Molecular Screening and Therapeutic (MoST) Program are similar nonrandomized, multidrug, pan-cancer trial platforms that aim to identify signals of clinical activity of molecularly matched targeted therapies or immunotherapies outside their approved indications. Here, we report results for advanced or metastatic cancer patients with tumors harboring cyclin D-CDK4/6 pathway alterations treated with CDK4/6 inhibitors palbociclib or ribociclib. We included adult patients that had therapy-refractory solid malignancies with the following alterations: amplifications of CDK4, CDK6, CCND1, CCND2 or CCND3, or complete loss of CDKN2A or SMARCA4. Within MoST, all patients were treated with palbociclib, whereas in DRUP, palbociclib and ribociclib were assigned to different cohorts (defined by tumor type and alteration). The primary endpoint for this combined analysis was clinical benefit, defined as confirmed objective response or stable disease ≥16 weeks. We treated 139 patients with a broad variety of tumor types; 116 with palbociclib and 23 with ribociclib. In 112 evaluable patients, the objective response rate was 0% and clinical benefit rate at 16 weeks was 15%. Median progression-free survival was 4 months (95% CI: 3-5 months), and median overall survival 5 months (95% CI: 4-6 months). In conclusion, only limited clinical activity of palbociclib and ribociclib monotherapy in patients with pretreated cancers harboring cyclin D-CDK4/6 pathway alterations was observed. Our findings indicate that monotherapy use of palbociclib or ribociclib is not recommended and that merging data of two similar precision oncology trials is feasible. 相似文献
42.
Michala G. Rolver Lya K. K. Holland Muthulakshmi Ponniah Nanditha S. Prasad Jiayi Yao Julie Schnipper Signe Kramer Line Elingaard-Larsen Elena Pedraz-Cuesta Bin Liu Luis A. Pardo Kenji Maeda Albin Sandelin Stine Falsig Pedersen 《International journal of cancer. Journal international du cancer》2023,152(8):1668-1684
The mechanisms linking tumor microenvironment acidosis to disease progression are not understood. Here, we used mammary, pancreatic, and colon cancer cells to show that adaptation to growth at an extracellular pH (pHe) mimicking acidic tumor niches is associated with upregulated net acid extrusion capacity and elevated intracellular pH at physiological pHe, but not at acidic pHe. Using metabolic profiling, shotgun lipidomics, imaging and biochemical analyses, we show that the acid adaptation-induced phenotype is characterized by a shift toward oxidative metabolism, increased lipid droplet-, triacylglycerol-, peroxisome content and mitochondrial hyperfusion. Peroxisome proliferator-activated receptor-α (PPARA, PPARα) expression and activity are upregulated, at least in part by increased fatty acid uptake. PPARα upregulates genes driving increased mitochondrial and peroxisomal mass and β-oxidation capacity, including mitochondrial lipid import proteins CPT1A, CPT2 and SLC25A20, electron transport chain components, peroxisomal proteins PEX11A and ACOX1, and thioredoxin-interacting protein (TXNIP), a negative regulator of glycolysis. This endows acid-adapted cancer cells with increased capacity for utilizing fatty acids for metabolic needs, while limiting glycolysis. As a consequence, the acid-adapted cells exhibit increased sensitivity to PPARα inhibition. We conclude that PPARα is a key upstream regulator of metabolic changes favoring cancer cell survival in acidic tumor niches. 相似文献
43.
Jacey Nishiguchi Anusha McNamara Colleen S. Surlyn Kellene Vokaty Eagen Laura Feeney Vivian Lian David E. Smith 《Journal of viral hepatitis》2022,29(1):21-25
In 2016, an eConsult service was developed within a safety net health system to expand access to hepatitis C (HCV) treatment in the primary care setting. The eConsult system provides individualized treatment recommendations from specially trained primary care pharmacists and primary care physicians to primary care providers with less experience in the rapidly changing treatment of HCV. Since its launch, this service has had a large impact in expanding care to a largely homeless and low-income urban population within our health system. We now aim to evaluate its efficacy in curing HCV. In this retrospective cohort study, we describe rates of sustained virologic response 12 weeks after treatment completion (SVR12) for those who received primary care-based HCV treatment through the eConsult system with those who were treated in primary care independent of an eConsult from 2017 to 2019. We found there was no significant difference in the proportion of patients who achieved SVR12 between the two groups. Overall, >90% of patients who received treatment achieved SVR12. Approximately 40% of patients treated for HCV received an eConsult, suggesting utility of the eConsult in expanding access and coordinating treatment for patients within our network. 相似文献
44.
45.
Melanie Y. T. Chan Arbab Anwar William J. S. Lockley 《Journal of labelled compounds & radiopharmaceuticals》2022,65(4):101-111
Base catalysed exchange with sodium hydroxide, calcium oxide or N,N,N,N-tetramethylguanidine in deuterium oxide is a viable procedure for the preparation of terminally deuterated alkynes for those alkynes stable to strong base. The use of silver perchlorate as a catalyst is an alternative practical option when labelling alkynes which are sensitive to base or contain functionalities which would lead to labelling elsewhere in the molecule. Labelling with this catalyst takes place smoothly at ambient temperature in a mixture of N,N-dimethylformamide and deuterium oxide. 相似文献
46.
47.
48.
Lillyblad Matthew P. Qadri Ghaziuddin A. Weise Brynn E. Smith Claire S. St. Hill Catherine Tierney David M. Melamed Roman R. 《Journal of thrombosis and thrombolysis》2022,54(4):605-615
Journal of Thrombosis and Thrombolysis - Alteplase treatment can cause a systemic coagulopathy although the incidence and contributory factors are unknown in pulmonary embolism (PE). Fixed-dosing... 相似文献
49.
Kolomeets Natalya S. Uranova Natalya A. 《European archives of psychiatry and clinical neuroscience》2022,272(6):947-955
European Archives of Psychiatry and Clinical Neuroscience - Neuroimaging, genetic and molecular biological studies have shown impaired intra-cortical myelination in patients with schizophrenia,... 相似文献